Medicare reverses a brain tumor drug decision

by John Fauber

Paula Oertel’s brain tumor disappeared for nine years while she was on a drug not approved for her condition. The tumor returned when a move to a new home triggered a Medicare review — and subsequent denial of coverage for the experimental treatment.

Now Medicare officials have decided she will be allowed to go back on the drug.

“I am hoping …

Read more…

Medicare reverses a brain tumor drug decision

Medicare denies a brain tumor drug after a patient moves

by John Fauber

For nearly a decade, Paula Oertel’s brain tumor was kept at bay by a drug that was not approved to treat her condition. Then Oertel did something she never imagined would jeopardize her health.

She moved — less than 30 miles — from one county in Wisconsin to another.

That move triggered a review of her health insurance from Medicare, which eventually led to a loss of coverage, including …

Read more…

Medicare denies a brain tumor drug after a patient moves

Cancer deaths are improving, but a cure remains distant

Originally published in MedPage Today

by Joyce Frieden, MedPage Today News Editor

Almost 40 years and 100 billion federal dollars have been invested in the “War On Cancer” since President Richard M. Nixon declared it, but the campaign is far from over, two researchers concluded this week in the Journal of the American Medical Association.

“These funds have been more than matched by …

Read more…

Cancer deaths are improving, but a cure remains distant

Cancer side effects are being ignored by the media

Originally published in MedPage Today

by John Gever, MedPage Today Senior Editor

When the mainstream media report on cancer treatments, they seldom note that aggressive therapies may fail or cause severe side effects, researchers said.

Analyzing more than 400 articles about cancer in major newspapers and magazines, investigators at the University of Pennsylvania found that adverse outcomes or palliative care were hardly …

Read more…

Cancer side effects are being ignored by the media

ADVERTISEMENT

PSA for prostate cancer screening is likely to continue

Originally published in MedPage Today

by Crystal Phend

The ASCO Genitourinary Cancers Symposium met recently, just after the American Cancer Society updated its prostate cancer screening guidelines to emphasize shared decision making and Congress heard testimony over use of prostate specific antigen (PSA) in prostate cancer screening.

Now urology is no stranger to debate. Controversy continues on overdiagnosis, overtreatment, and other issues raised …

Read more…

PSA for prostate cancer screening is likely to continue

PSA screening for prostate cancer debated in Congress

Originally posted in MedPage Today

by Emily P. Walker, MedPage Today Washington Correspondent

A day after the American Cancer Society (ACS) released updated prostate cancer screening guidelines, the group’s chief medical officer was before Congress urging the government to fund research into alternative screening methods for prostate cancer.

Otis Brawley, MD, an oncologist and chief medical officer for the ACS, told the House Oversight …

Read more…

PSA screening for prostate cancer debated in Congress

Balancing the risks and benefits of cancer screening is an individual decision

by Abraham Verghese, MD

I can’t get over the incredible images generated by our latest CT scans and MRI’s. The details of organ anatomy and the 3D reconstructions they can do are just amazing. One side effect of getting such fine resolution, is that more and more we are stumbling onto abnormalities that we were not necessarily looking for–incidentalomas, we call them.

Sometimes the discovery is fortuitous and lifesaving. But often …

Read more…

Balancing the risks and benefits of cancer screening is an individual decision

Linking the USPSTF mammogram guidelines to their virtual colonoscopy recommendations

by Mark E. Klein, MD

“I think anytime you use science to kind of fundamentally change what people are used to, I think it’s a difficult thing to grapple with.” So spoke Ned Calonge, chair of the United States Preventive Services Task Force (USPSTF) in explaining the reaction to that group’s recommendation to radically alter their previous guidelines for breast cancer screening. Regrettably the incorrect application of science, as in …

Read more…

Linking the USPSTF mammogram guidelines to their virtual colonoscopy recommendations

86
pages